



---

## Liquid Biopsy Cancer Screening and Detection

Analyst & Investor  
Conference Call  
FY 2021

---





# SAFE HARBOR STATEMENT

---

## Forward Looking Statements

This communication contains certain forward-looking statements, including, without limitation, statements containing the words “expects”, “future”, “potential” and words of similar import.


Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements.

We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

# Epi proColon “Next-Gen” Assay for CRC





# ADDITIONAL OPERATIONAL DEVELOPMENTS

---

## Legislative Activities

- Company continues to pursue Medicare reimbursement via legislation for Epi proColon

## Current and Future Capital Measures

- 2021 - Aggregate raises of EUR 24.2 million in gross proceeds providing liquidity well into 2023
- Company will need to raise additional capital to complete trial and subsequent FDA approval
  - Company exploring numerous financing activities including potentially other exchanges that provide greater access to capital



# FY 2021 RESULTS

## FY 2021 Financial Highlights

EURm	FY 2021	FY 2020	Variance
REVENUE	6.2	0.8	5.4
ADJ. EBITDA*	(1.8)	(10.5)	8.7
NET RESULT	(2.4)	(11.7)	9.3
CASH CONSUMPTION	(4.2)	(9.6)	5.4
	Dec. 31, 2021	Dec 31, 2020	
Liquid Assets **	23.0	3.6	19.4

## 2022 Financial Outlook

Revenue  
EUR 0.3m  
to 0.8m

EBITDA\*  
EUR -15.0m  
to -17.0m

Cash Burn  
EUR -15.0m  
to -17.0m

\*EBITDA before share-based payment expenses  
\*\*Cash and cash equivalents





---

## Q&A Session

Analyst & Investor  
Conference Call  
FY 2021

---